# DESCRIPTION

## BACKGROUND

- introduce GABA and immune system

## SUMMARY

- summarize GABA's effects on autoimmune responses

## Embodiment 1

- describe method of reducing inflammatory immune response

## Embodiment 2

- specify reducing inflammatory immune response

## Embodiment 3

- specify T cell proliferation

## Embodiment 4

- specify promoting regulatory immune response

## Embodiment 5

- inhibit Th1-mediated immune response

### Embodiment 6

- downregulate inflammatory cytokines or chemokines

### Embodiment 7

- downregulate specific inflammatory cytokines or chemokines

### Embodiment 8

- downregulate IL-1

### Embodiment 9

- downregulate IL-12

### Embodiment 10

- downregulate IL-6

### Embodiment 11

- downregulate TNF

### Embodiment 12

- downregulate IFN-Î³

### Embodiment 13

- downregulate GMCSF and IL-23

### Embodiment 14

- downregulate IL-23

### Embodiment 15

- reduce inflammation-related T-cell types

### Embodiment 16

- reduce CD8+ T cells

### Embodiment 17

- reduce Th17 cells

### Embodiment 18

- increase regulatory T cells

### Embodiment 19

- administer PAM with GABA receptor activating ligand

### Embodiment 20

- combination of PAM and GABA receptor activating ligand is more effective

### Embodiment 21

- quantify increased effectiveness of combination

### Embodiment 22

- use lower dosages of GABA receptor activating ligand and/or PAM

### Embodiment 23

- quantify lower dosage of GABA receptor activating ligand

### Embodiment 24

- quantify lower dosage of PAM

### Embodiment 25

- use lower dosages of GABA receptor activating ligand and/or PAM

### Embodiment 26

- treat human

### Embodiment 27

- treat human with type I diabetes

### Embodiment 28

- treat human who is pre-diabetic

### Embodiment 29

- treat non-human mammal

### Embodiment 30

- PAM and GABA receptor activating ligand act synergistically

### Embodiment 31

- PAM is selected from group of agents

### Embodiment 32

- PAM is barbituate

### Embodiment 33

- PAM is specific barbiturate

### Embodiment 34

- PAM is benzodiazepine

### Embodiment 35

- PAM is specific benzodiazepine

### Embodiment 36

- PAM is alprazolam

### Embodiment 37

- administer alprazolam at lower dosage

### Embodiment 38

- quantify lower dosage of alprazolam

### Embodiment 39

- PAM is midazolam

### Embodiment 40

- administer midazolam at lower dosage

### Embodiment 41

- quantify lower dosage of midazolam

### Embodiment 42

- PAM is clonazepam

### Embodiment 43

- administer clonazepam at lower dosage

### Embodiment 44

- quantify lower dosage of clonazepam

### Embodiment 45

- PAM is neurosteroid

### Embodiment 46

- PAM is specific neurosteroid

### Embodiment 47

- PAM is selected from group of agents

### Embodiment 48

- PAM is AP325

### Embodiment 49

- administer AP325 at lower dosage

### Embodiment 50

- GABA receptor activating ligand is GABA

### Embodiment 51

- GABA receptor activating ligand is selected from group of agents

### Embodiment 52

- GABA receptor activating ligand is not an alcohol

### Embodiment 53

- GABA receptor activating ligand is not a kavalactone

### Embodiment 54

- GABA receptor activating ligand is not skullcap or a skullcap constituent

### Embodiment 55

- GABA receptor activating ligand is not valerian or a valerian constituent

### Embodiment 56

- GABA receptor activating ligand is not a volatile gas

### Embodiment 57

- treat inflammatory disease

### Embodiment 58

- treat specific inflammatory disease

### Embodiment 59

- prevent or lessen graft rejection

### Embodiment 60

- reduce allergic response

### Embodiment 61

- reduce allergic response in specific condition

### Embodiment 62

- mammal is not under treatment for specific conditions

### Embodiment 63

- PAM is not administered for specific purposes

### Embodiment 64

- administer BBB-permeable PAMs at lower doses

### Definitions

- define terms

### DETAILED DESCRIPTION

- describe discovery of PAMs reducing inflammatory immune response
- describe synergistic effect of PAMs with GABA receptor activating ligands
- describe methods of reducing inflammatory immune response and/or promoting regulatory immune response
- describe pharmaceutical formulations and kits for practice of methods

### GABAA Receptor Positive Allosteric Modulators (PAMs)

- list illustrative PAMs

### GABA Receptor Activating Ligands

- list illustrative GABA receptor activating ligands

### Combined Formulations

- introduce combined formulations of GABA receptor activating ligands and PAMs
- describe GABA receptor activating ligands
- describe PAMs
- formulate active agents as salts, esters, amides, prodrugs, and derivatives
- prepare pharmaceutically acceptable salts
- prepare esters
- prepare amides
- combine active agents with pharmaceutically acceptable carriers
- manufacture pharmaceutical compositions
- formulate for various routes of administration
- determine dosage and administration schedule

### Kits

- provide kit components and instructions

### EXAMPLES

- describe PAM and GABA receptor interaction
- demonstrate combination therapy effectiveness

